Does HPLC Expose a Bee Venom Quality Blind Spot?

Honeybee venom has been gaining attention as a promising raw material for medicine, particularly for potential uses in brain-related research and cancer treatment. But even though the venom is chemically complex, made up of many different components, current industry standards for judging its quality still mostly rely on measuring just one substance, called melittin. This overlooks the fact that all the different components in the venom work together and depend on one another.

To address this gap, Mehmet Beykaya of Turkey's Ministry of Agriculture and Forestry took a closer look at what he calls the "melittin-equivalence paradox." This refers to a strange pattern where different batches of bee venom can have almost identical amounts of melittin, and yet still differ significantly in other important ways, such as their enzyme content and how toxic they are to the nervous system. Beykaya used a high-performance liquid chromatography (HPLC) framework to analyze 25 batches of bee venom collected from different ecological regions across Turkey. A paper based on his efforts was published in was published in the Journal of Chromatography B.¹

Why is Bee Venom Gaining Attention as a Potential Source of New Medicines?

Honeybee venom, also called apitoxin, is a complex substance produced by honeybees' venom glands, and it's increasingly being recognized as a rich source of potentially valuable compounds for medicine.^2,3 Bee venom has long been used in traditional medicine, but modern research has shifted how scientists view it; they no longer just seeing it as a defense mechanism bees use to protect themselves, but as a promising candidate for developing new drugs. Studies have shown it can have a wide range of effects on the body, including potential anti-cancer, anti-inflammatory, and antimicrobial properties.^4-6

Large-scale reviews that combine and analyze results from multiple studies have confirmed that bee venom can be effective in real-world treatment settings, especially for managing long-term joint and muscle conditions, and even in dealing with certain viral infections. This growing evidence makes it more critical to develop strict, reliable standards for testing and evaluating venom quality.^7,8

What is Melittin?

Bee venom's potential as a cancer treatment mostly comes down to melittin, a small protein-like molecule made up of 26 amino acids. Melittin has been shown to effectively destroy the membranes of various types of cancer cells.^9,10 Melittin has shown the ability to trigger cancer cell death in certain hard-to-treat cancers, including glioblastoma (a type of brain cancer), as well as lung and breast cancer, by disrupting key signaling pathways that these cancer cells rely on to survive and grow. Because of this, melittin has become one of the most promising molecules being studied for targeted cancer treatments.^11,12 

Is Melittin Content Alone a Reliable Indicator of Bee Venom Quality?

Beykaya’s analysis found that, on average, bee venom samples contained about 36% melittin, 14% of an enzyme called phospholipase A2 (PLA2), and roughly 2% apamin (another venom component). When Beykaya compared specific samples with nearly the same melittin levels (for example, two samples with about 32% melittin each), he found that other properties, like PLA2 levels and moisture content, varied quite a bit between them, even though melittin was basically the same.¹

Further statistical analysis supported this finding, showing that the amount of melittin in a sample does not reliably predict the rest of its chemical makeup. In other words, the different components of bee venom don't necessarily rise and fall together, which means melittin alone isn't a good stand-in for judging the venom's overall quality.¹

“The findings, Beykaya wrote in his paper,¹ “suggest that the ‘melittin-equivalence’ often observed in traditional protocols is a univariate oversimplification that masks fundamental differences in stability and safety. The proposed MVQA framework provides a metrological roadmap for the standardization of bee venom, ensuring therapeutic consistency and safety through advanced chemometric protocols that go beyond single-parameter proxies.”

References

1. Beykaya, M. Chemometric-Based Analytical Standardization of Bee Venom: Resolving the Melittin-Equivalence Paradox Through Multivariate Quality Assurance. J Chromatogr B Analyt Technol Biomed Life Sci. 2026,1281,125207. DOI: 10.1016/j.jchromb.2026.125207
2. Habermann, H. Bee and Wasp Venoms. Science 1972,177, 314-322. DOI: 10.1126/science.177.4046.314
3. Oršolić, I. Bee Venom in Cancer Therapy: A Review. Cancer Metastasis Rev.2012, 31, 173-194. DOI: 10.1007/s10555-011-9339-3
4. Wehbe, R.; Frangieh, J.; Rima, M. et al. Bee Venom: Overview of Main Compounds and Bioactivities for Therapeutic Interests. Molecules 2019,24 (16), 2997. DOI: 10.3390/molecules24162997
5. Sadek, K. M.; Shib, N. A.; Taher, E. S. et al. Harnessing the Power of Bee Venom for Therapeutic and Regenerative Medical Applications: An Updated Review. Front Pharmacol. 2024, 15, 1412245. DOI: 10.3389/fphar.2024.1412245
6. Sleman, S.; Abass, Z. A.; Abdullah, B. J. et al. Honeybee Venom Therapy and Viral Infection: A Systematic Synthesis of Venom Antiviral Activity. Front. Virol. 2026, 12, 1751614. DOI: 10.3389/fviro.2026.1751614
7. Park, J. H.;Yim, B. K.; Lee, J. H. et al. Risk Associated with Bee Venom Therapy: A Systematic Review and Meta-Analysis. PLoS One2015,10 (5), e0126971. DOI: 10.1371/journal.pone.0126971
8. Jang, S.; Kim, K. H. Clinical Effectiveness and Adverse Events of Bee Venom Therapy: A Systematic Review of Randomized Controlled Trials. Toxins (Basel) 2020, 12 (9), 558. DOI: 10.3390/toxins12090558
9. Gajski, G.; Leonova, E.; Sjakste, N. Bee Venom: Composition and Anticancer Properties. Toxins (Basel). 2024, 16 (3), 117. DOI: 10.3390/toxins16030117
10. Małek, A.; Strzemski, M.; Kurzepa, J. et al. Can Bee Venom Be Used as Anticancer Agent in Modern Medicine? Cancers (Basel) 2023, 15 (14), 3714. DOI: 10.3390/cancers15143714
11. Zhang, H. Q.; Wang, Y.; Geng, X. et al. ANG-Modified Liposomes Coloaded With α-Melittin and Resveratrol Induce Apoptosis and Pyroptosis in Glioblastoma Cells by Impeding Wnt/β-Catenin Signaling. CNS Neurosci Ther. 2025, 31 (5), e70437. DOI: 10.1111/cns.70437
12. Li, Y. Mechanism of Melittin for Anti-Tumor Effects: Research Status and Future Perspectives. J. Clin. Technol. Theory2025, 2, 33-37. DOI:10.54254/3049-5458/2025.21076